NCT00701389View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 20, 2007

Primary Completion Date

April 10, 2008

Study Completion Date

April 10, 2008

Conditions

Migraine Disorders

Interventions

DRUG

telcagepant potassium

Single oral dose of 2 x 300 mg capsules.

DRUG

sumatriptan

single oral dose of 100 mg sumatriptan

DRUG

sumatriptan placebo

single oral dose

DRUG

telcagepant potassium placebo

single oral dose of 2 MK-0974 placebo capsules

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00701389 - Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026) | Biotech Hunter | Biotech Hunter